{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:25:11Z","timestamp":1791332711310,"version":"4.3.1"},"reference-count":120,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>The transforming growth factor (TGF)-\u03b2 superfamily has important physiologic roles and is dysregulated in many pathologic processes, including pancreatic cancer. Pancreatic cancer is one of the most lethal cancer diagnoses, and current therapies are largely ineffective due to tumor resistance and late-stage diagnosis with poor prognosis. Recent efforts are focused on the potential of immunotherapies in improving therapeutic results for patients with pancreatic cancer, among which TGF-\u03b2 has been identified as a promising target. This review focuses on the role of TGF-\u03b2 in the diseased pancreas and pancreatic cancer. It also aims to summarize the current status of therapies targeting the TGF-\u03b2 superfamily and postulate potential future directions in targeting the TGF-\u03b2 signaling pathways.<\/jats:p>","DOI":"10.3389\/fonc.2024.1362247","type":"journal-article","created":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T04:28:10Z","timestamp":1709526490000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["The TGF-\u03b2 superfamily as potential therapeutic targets in pancreatic cancer"],"prefix":"10.3389","volume":"14","author":[{"given":"Rachel R.","family":"Tindall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer M.","family":"Bailey-Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanna","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tien C.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2580","article-title":"New insights into the regulation of T cells by gamma(c) family cytokines","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-273417","article-title":"Interleukin-1 in the pathogenesis and treatment of inflammatory diseases","volume":"117","author":"Dinarello","year":"2011","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.15.1.749","article-title":"Cellular responses to interferon-gamma","volume":"15","author":"Boehm","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1074-7613(00)80165-X","article-title":"Chemokines: a new classification system and their role in immunity","volume":"12","author":"Zlotnik","year":"2000","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.17.1.331","article-title":"Tumor necrosis factor receptor and Fas signaling mechanisms","volume":"17","author":"Wallach","year":"1999","journal-title":"Annu Rev Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.75.8.4001","article-title":"Growth factors from murine sarcoma virus-transformed cells","volume":"75","author":"de Larco","year":"1978","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B7","article-title":"Transforming growth factor production by chemically transformed cells","volume":"41","author":"Moses","year":"1981","journal-title":"Cancer Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.78.9.5339","article-title":"New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues","volume":"78","author":"Roberts","year":"1981","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(87)90192-9","article-title":"The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors","volume":"48","author":"Cheifetz","year":"1987","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1002\/embj.1988.7.issue-12","article-title":"A new type of transforming growth factor-beta, TGF-beta 3","volume":"7","author":"Derynck","year":"1988","journal-title":"EMBO J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.85.13.4715","article-title":"Identification of another member of the transforming growth factor type beta gene family","volume":"85","author":"ten Dijke","year":"1988","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.3201241","article-title":"Novel regulators of bone formation: molecular clones and activities","volume":"242","author":"Wozney","year":"1988","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021873","article-title":"TGF-beta and the TGF-beta family: context-dependent roles in cell and tissue physiology","volume":"8","author":"Morikawa","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021899","article-title":"Bone morphogenetic proteins","volume":"8","author":"Katagiri","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.cellsig.2018.09.004","article-title":"TGFbeta, smooth muscle cells and coronary artery disease: a review","volume":"53","author":"Low","year":"2019","journal-title":"Cell Signal"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021881","article-title":"Activins and inhibins: roles in development, physiology, and disease","volume":"8","author":"Namwanje","year":"2016","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau2909","article-title":"Structural basis of latent TGF-beta1 presentation and activation by GARP on human regulatory T cells","volume":"362","author":"Lienart","year":"2018","journal-title":"Science"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2008.01.012","article-title":"Integrins and the activation of latent transforming growth factor beta1 - an intimate relationship","volume":"87","author":"Wipff","year":"2008","journal-title":"Eur J Cell Biol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.028506","article-title":"Site-specific cleavage of BMP4 by furin, PC6, and PC7","volume":"284","author":"Nelsen","year":"2009","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-3827","article-title":"The propeptide mediates formation of stromal stores of PROMIC-1: role in determining prostate cancer outcome","volume":"65","author":"Bauskin","year":"2005","journal-title":"Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M006933200","article-title":"Lefty proteins exhibit unique processing and activate the MAPK pathway","volume":"276","author":"Ulloa","year":"2001","journal-title":"J Biol Chem"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-10-183","article-title":"TGF-beta - an excellent servant but a bad master","volume":"10","author":"Kubiczkova","year":"2012","journal-title":"J Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2008.328","article-title":"Non-Smad pathways in TGF-beta signaling","volume":"19","author":"Zhang","year":"2009","journal-title":"Cell Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1208","article-title":"Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer","volume":"3","author":"Siegel","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/BF00383771","article-title":"Mesodermal induction in early amphibian embryos by activin A (erythroid differentiation factor)","volume":"198","author":"Asashima","year":"1990","journal-title":"Rouxs Arch Dev Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00951","article-title":"Growth\/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint","volume":"11","author":"Wischhusen","year":"2020","journal-title":"Front Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M010783200","article-title":"Lefty inhibits receptor-regulated Smad phosphorylation induced by the activated transforming growth factor-beta receptor","volume":"276","author":"Ulloa","year":"2001","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.163.5.1037","article-title":"Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth","volume":"163","author":"Kehrl","year":"1986","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030152","article-title":"Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3","volume":"198","author":"Chen","year":"2003","journal-title":"J Exp Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1607","article-title":"A critical function for TGF-beta signaling in the development of natural CD4+CD25+Foxp3+ regulatory T cells","volume":"9","author":"Liu","year":"2008","journal-title":"Nat Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)32345-7","article-title":"Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization","volume":"258","author":"Assoian","year":"1983","journal-title":"J Biol Chem"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.84.16.5788","article-title":"Transforming growth factor type beta induces monocyte chemotaxis and growth factor production","volume":"84","author":"Wahl","year":"1987","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1084\/jem.165.1.251","article-title":"Stimulation of the chemotactic migration of human fibroblasts by transforming growth factor beta","volume":"165","author":"Postlethwaite","year":"1987","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2019.12.010","article-title":"TGF-beta1 - A truly transforming growth factor in fibrosis and immunity","volume":"101","author":"Lodyga","year":"2020","journal-title":"Semin Cell Dev Biol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-beta signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.83.12.4167","article-title":"Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro","volume":"83","author":"Roberts","year":"1986","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119590","article-title":"Adenovector-mediated gene transfer of active transforming growth factor-beta1 induces prolonged severe fibrosis in rat lung","volume":"100","author":"Sime","year":"1997","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-011-1246-y","article-title":"TGF-beta in progression of liver disease","volume":"347","author":"Dooley","year":"2012","journal-title":"Cell Tissue Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.cels.2018.08.010","article-title":"A pan-cancer analysis reveals high-frequency genetic alterations in mediators of signaling by the TGF-beta superfamily","volume":"7","author":"Korkut","year":"2018","journal-title":"Cell Syst"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5089","article-title":"Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype","volume":"68","author":"Bharathy","year":"2008","journal-title":"Cancer Res"},{"key":"B41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/40431","article-title":"A structural basis for mutational inactivation of the tumour suppressor Smad4","volume":"388","author":"Shi","year":"1997","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1159\/000085265","article-title":"Pathophysiology of acute pancreatitis","volume":"5","author":"Bhatia","year":"2005","journal-title":"Pancreatology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2004.tb00330.x","article-title":"Apoptosis of pancreatic acinar cells in acute pancreatitis: is it good or bad","volume":"8","author":"Bhatia","year":"2004","journal-title":"J Cell Mol Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1172\/JCI119418","article-title":"Overexpression of the TGFbeta-regulated zinc finger encoding gene, TIEG, induces apoptosis in pancreatic epithelial cells","volume":"99","author":"Tachibana","year":"1997","journal-title":"J Clin Invest"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431X20165388","article-title":"Galunisertib (LY2157299), a transforming growth factor-beta receptor I kinase inhibitor, attenuates acute pancreatitis in rats","volume":"49","author":"Liu","year":"2016","journal-title":"Braz J Med Biol Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31825b9f2c","article-title":"Noggin attenuates cerulein-induced acute pancreatitis and impaired autophagy","volume":"42","author":"Cao","year":"2013","journal-title":"Pancreas"},{"key":"B48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-032713-120257","article-title":"TGF-beta activation and function in immunity","volume":"32","author":"Travis","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2012.02.001","article-title":"The symphony of the ninth: the development and function of Th9 cells","volume":"24","author":"Jabeen","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0000000000000284","article-title":"Increased interleukin-23\/17 axis and C-reactive protein are associated with severity of acute pancreatitis in patients","volume":"44","author":"Jia","year":"2015","journal-title":"Pancreas"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.03.001","article-title":"Chronic pancreatitis: challenges and advances in pathogenesis, genetics, diagnosis, and therapy","volume":"132","author":"Witt","year":"2007","journal-title":"Gastroenterology"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2012.00344","article-title":"Pancreatic stellate cells: a starring role in normal and diseased pancreas","volume":"3","author":"Apte","year":"2012","journal-title":"Front Physiol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1097\/01.mpa.0000157388.54016.0a","article-title":"Amelioration of pancreatic fibrosis in mice with defective TGF-beta signaling","volume":"30","author":"Yoo","year":"2005","journal-title":"Pancreas"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.2001.280.1.G164","article-title":"Effects of fibrogenic mediators on the development of pancreatic fibrosis in a TGF-beta1 transgenic mouse model","volume":"280","author":"Vogelmann","year":"2001","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)61125-X","article-title":"Expression of transforming growth factor-beta 1 by pancreatic stellate cells and its implications for matrix secretion and turnover in chronic pancreatitis","volume":"160","author":"Shek","year":"2002","journal-title":"Am J Pathol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00306.2012","article-title":"BMP2 inhibits TGF-beta-induced pancreatic stellate cell activation and extracellular matrix formation","volume":"304","author":"Gao","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0089114","article-title":"Bone morphogenetic protein signaling protects against cerulein-induced pancreatic fibrosis","volume":"9","author":"Gao","year":"2014","journal-title":"PLoS One"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-015-1308-9","article-title":"Gremlin is a key pro-fibrogenic factor in chronic pancreatitis","volume":"93","author":"Staloch","year":"2015","journal-title":"J Mol Med (Berl)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2016.06.017","article-title":"Cerulein-induced pancreatic fibrosis is modulated by Smad7, the major negative regulator of transforming growth factor-beta signaling","volume":"1862","author":"Li","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/s0962-8924(01)02130-4","article-title":"TGF-beta signaling in cancer\u2013a double-edged sword","volume":"11","author":"Akhurst","year":"2001","journal-title":"Trends Cell Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13205086","article-title":"TGFbeta signaling in the pancreatic tumor microenvironment","volume":"13","author":"Principe","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(99)70024-7","article-title":"Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo","volume":"116","author":"Kleeff","year":"1999","journal-title":"Gastroenterology"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04888-7","article-title":"GREM1 is required to maintain cellular heterogeneity in pancreatic cancer","volume":"607","author":"Lan","year":"2022","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.gendis.2020.05.001","article-title":"Pancreatic stromal Gremlin 1 expression during pancreatic tumorigenesis","volume":"9","author":"Davis","year":"2022","journal-title":"Genes Dis"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pathmechdis.3.121806.154305","article-title":"Pancreatic cancer","volume":"3","author":"Maitra","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5247.350","article-title":"DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1","volume":"271","author":"Hahn","year":"1996","journal-title":"Science"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0084366","article-title":"Loss of canonical Smad4 signaling promotes KRAS driven Malignant transformation of human pancreatic duct epithelial cells and metastasis","volume":"8","author":"Leung","year":"2013","journal-title":"PloS One"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/science.1071809","article-title":"Signal transduction by the TGF-beta superfamily","volume":"296","author":"Attisano","year":"2002","journal-title":"Science"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.25.18.8108-8125.2005","article-title":"Smad4 dependency defines two classes of transforming growth factor beta (TGF-beta) target genes and distinguishes TGF-beta-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses","volume":"25","author":"Levy","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.806963","article-title":"Loss of SMAD4 is associated with poor tumor immunogenicity and reduced PD-L1 expression in pancreatic cancer","volume":"12","author":"Principe","year":"2022","journal-title":"Front Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202103029","article-title":"Smad4 deficiency promotes pancreatic cancer immunogenicity by activating the cancer-autonomous DNA-sensing signaling axis","volume":"9","author":"Xiong","year":"2022","journal-title":"Adv Sci (Weinh)"},{"key":"B72","article-title":"Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas","volume":"58","author":"Goggins","year":"1998","journal-title":"Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgm249","article-title":"Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression","volume":"29","author":"Gordon","year":"2008","journal-title":"Carcinogenesis"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-126","article-title":"Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer","volume":"13","author":"Togashi","year":"2014","journal-title":"Mol Cancer"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1086\/323703","article-title":"Germline mutations in BMPR1A\/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes","volume":"69","author":"Zhou","year":"2001","journal-title":"Am J Hum Genet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5316.1268","article-title":"Gene expression profiles in normal and cancer cells","volume":"276","author":"Zhang","year":"1997","journal-title":"Science"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible","volume":"13","author":"Cox","year":"2014","journal-title":"Nat Rev Drug Discovery"},{"key":"B78","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1593\/neo.04445","article-title":"Frequency of K-ras mutations in pancreatic intraductal neoplasias associated with pancreatic ductal adenocarcinoma and chronic pancreatitis: a meta-analysis","volume":"7","author":"Lohr","year":"2005","journal-title":"Neoplasia"},{"key":"B79","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ng.2263","article-title":"Hereditary mixed polyposis syndrome is caused by a 40-kb upstream duplication that leads to increased and ectopic expression of the BMP antagonist GREM1","volume":"44","author":"Jaeger","year":"2012","journal-title":"Nat Genet"},{"key":"B80","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nm.3750","article-title":"Aberrant epithelial GREM1 expression initiates colonic tumorigenesis from cells outside the stem cell niche","volume":"21","author":"Davis","year":"2015","journal-title":"Nat Med"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.6.2403","article-title":"Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial","volume":"15","author":"Burris","year":"1997","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2959","article-title":"Long-term gemcitabine treatment reshapes the pancreatic tumor microenvironment and sensitizes murine carcinoma to combination immunotherapy","volume":"80","author":"Principe","year":"2020","journal-title":"Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2011.01917.x","article-title":"Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer","volume":"102","author":"Schlingensiepen","year":"2011","journal-title":"Cancer Sci"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.4034","article-title":"Final results of a phase I\/II study in patients with pancreatic cancer, Malignant melanoma, and colorectal carcinoma with trabedersen","volume":"30","author":"Oettle","year":"2012","journal-title":"J Clin Oncol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay8456","article-title":"Selective inhibition of TGFbeta1 activation overcomes primary resistance to checkpoint blockade therapy by altering tumor immune landscape","volume":"12","author":"Martin","year":"2020","journal-title":"Sci Transl Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-SITC2022.0780","article-title":"780 SRK-181, a latent TGF\u03b21 inhibitor: safety, efficacy, and biomarker results from the dose escalation portion of a phase I trial (DRAGON trial) in patients with advanced solid tumors","volume":"10","author":"Yap","year":"2022","journal-title":"J ImmunoTherapy Cancer"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12855","article-title":"Model informed dosing regimen and phase I results of the anti-PD-1 antibody budigalimab (ABBV-181)","volume":"14","author":"Powderly","year":"2021","journal-title":"Clin Transl Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.1467","article-title":"1467 Selective targeting of integrins \u03b1V\u03b28 and \u03b1V\u03b21 within the dynamic ecosystem of pancreatic cancer to improve the overall anti-tumor response","volume":"11","author":"Fajardo","year":"2023","journal-title":"J ImmunoTherapy Cancer"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-SITC2023.0714","article-title":"714 Phase 1a trial of PLN-101095, an integrin \u03b1v\u03b28 and \u03b1v\u03b21 inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metastatic solid tumors","volume":"11","author":"Daud","year":"2023","journal-title":"J ImmunoTherapy Cancer"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1002\/path.5320","article-title":"The integrin alphavbeta6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy","volume":"249","author":"Reader","year":"2019","journal-title":"J Pathol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1053\/j.gastro.2023.05.038","article-title":"Transforming growth factor-beta blockade in pancreatic cancer enhances sensitivity to combination chemotherapy","volume":"165","author":"Qiang","year":"2023","journal-title":"Gastroenterology"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007353","article-title":"Phase I\/Ib, open-label, multicenter, dose-escalation study of the anti-TGF-\u03b2 monoclonal antibody, NIS793, in combination with spartalizumab in adult patients with advanced tumors","volume":"11","author":"Bauer","year":"2023","journal-title":"J ImmunoTherapy Cancer"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3245-5","article-title":"A phase 1 study of anti-TGFbeta receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors","volume":"79","author":"Tolcher","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2018-1759","article-title":"Abstract 1759: AVID200, a highly potent TGF-beta trap, exhibits optimal isoform selectivity for enhancing anti-tumor T-cell activity, without promoting metastasis or cardiotoxicity","volume":"78","author":"O'Connor-McCourt","year":"2018","journal-title":"Cancer Res"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2020-6710","article-title":"Abstract 6710: AVID200, a first-in-class selective TGF-beta 1 and -beta 3 inhibitor, sensitizes tumors to immune checkpoint blockade therapies","volume":"80","author":"Tremblay","year":"2020","journal-title":"Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.3587","article-title":"AVID200, first-in-class TGF-beta 1 and 3 selective and potent inhibitor: Safety and biomarker results of a phase I monotherapy dose-escalation study in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"J Exp Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s12929-017-0329-9","article-title":"Cancer immunotherapies targeting the PD-1 signaling pathway","volume":"24","author":"Iwai","year":"2017","journal-title":"J BioMed Sci"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1002\/1878-0261.13146","article-title":"Dual inhibition of TGF-beta and PD-L1: a novel approach to cancer treatment","volume":"16","author":"Gulley","year":"2022","journal-title":"Mol Oncol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1426519","article-title":"M7824, a novel bifunctional anti-PD-L1\/TGFbeta Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine","volume":"7","author":"Knudson","year":"2018","journal-title":"Oncoimmunology"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFbeta, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S86621","article-title":"Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway","volume":"9","author":"Herbertz","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0246-z","article-title":"Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer","volume":"119","author":"Melisi","year":"2018","journal-title":"Br J Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114716","article-title":"Vactosertib, TGF-beta receptor I inhibitor, augments the sensitization of the anti-cancer activity of gemcitabine in pancreatic cancer","volume":"162","author":"Lee","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B107","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41419-023-05630-5","article-title":"Combination treatment of T1-44, a PRMT5 inhibitor with Vactosertib, an inhibitor of TGF-beta signaling, inhibits invasion and prolongs survival in a mouse model of pancreatic tumors","volume":"14","author":"Hong","year":"2023","journal-title":"Cell Death Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.e16299","article-title":"Phase 1b study of vactosertib in combination with oxaliplatin with 5FU\/LV (FOLFOX) in patients with metastatic pancreatic cancer who have failed first-line gemcitabine\/nab-paclitaxel","volume":"40","author":"Kim","year":"2022","journal-title":"J Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-1504","article-title":"First-in-human phase I study of a next-generation, oral, TGFbeta receptor 1 inhibitor, LY3200882, in patients with advanced cancer","volume":"27","author":"Yap","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2289681","article-title":"Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer","volume":"15","author":"Davies","year":"2023","journal-title":"MAbs"},{"key":"B111","doi-asserted-by":"publisher","first-page":"4253","DOI":"10.1038\/s41467-023-39817-3","article-title":"Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment","volume":"14","author":"Haake","year":"2023","journal-title":"Nat Commun"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4394","article-title":"GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand","volume":"23","author":"Yang","year":"2017","journal-title":"Nat Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.4869","article-title":"Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients with metastatic pancreatic cancer: results from the PRODIGE 4\/ACCORD 11 randomized trial","volume":"31","author":"Gourgou-Bourgade","year":"2013","journal-title":"J Clin Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125","article-title":"Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer","volume":"384","author":"Kelly","year":"2021","journal-title":"N Engl J Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02616","article-title":"Immunologic strategies in pancreatic cancer: making cold tumors hot","volume":"40","author":"Ullman","year":"2022","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cancerbio-061421-040258","article-title":"Strategies for heating up cold tumors to boost immunotherapies","volume":"7","author":"Zabransky","year":"2023","journal-title":"Annu Rev Cancer Biol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgn274","article-title":"Bone morphogenetic proteins induce pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that involves matrix metalloproteinase-2","volume":"30","author":"Gordon","year":"2009","journal-title":"Carcinogenesis"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1111\/pin.12067","article-title":"Bi-directional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde","volume":"63","author":"Ehata","year":"2013","journal-title":"Pathol Int"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.117.029622","article-title":"Opposing actions of fibroblast and cardiomyocyte smad3 signaling in the infarcted myocardium","volume":"137","author":"Kong","year":"2018","journal-title":"Circulation"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1362247\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T04:28:18Z","timestamp":1709526498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1362247\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":120,"alternative-id":["10.3389\/fonc.2024.1362247"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1362247","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]},"article-number":"1362247"}}